{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:25:05Z","timestamp":1788009905161,"version":"build-2784847793"},"reference-count":79,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Novel immunotherapies have generated high response rates and unique adverse effects among patients with relapsed or refractory acute lymphoblastic leukemia. Therapies engaging endogenous T-cells against acute lymphoblastic leukemia are emerging for children and adults with various poor prognostic factors, thus accurate knowledge of immunotherapies is necessary for their effective implementation in the future. In this review, we evaluate clinical trial data regarding chimeric antigen receptor T-cells and blinatumomab, for the treatment of relapsed or refractory acute lymphoblastic leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>In the relapsed or refractory setting, response rates rapidly diminish after subsequent lines of chemotherapy and cumulative toxicities may cause significant patient harm. Immunotherapies provide an approach to improve response rates and minimize traditional toxicities via novel mechanisms of action. Two therapies targeting CD19 antigens expressed on B-cell acute lymphoblastic leukemia lineages, chimeric antigen receptor T-cells, and blinatumomab have induced complete remissions among high-risk patient populations, especially those refractory to multiple therapies. Adverse effects such as cytokine release syndrome and neurologic sequelae remain serious precautions of each therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Knowledge of immunotherapy mechanisms and clinical outcomes associated with immunotherapies is critical for the optimization of treating patients with relapsed or refractory acute lymphoblastic leukemia. Future use of chimeric antigen receptor T-cells and blinatumomab demands proper assessment of a patient\u2019s disease and treatment history in addition to unique monitoring and supportive care interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155217713363","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T01:10:19Z","timestamp":1496711419000},"page":"453-467","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia"],"prefix":"10.1177","volume":"24","author":[{"given":"Ryan K","family":"DasGupta","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The James Cancer Hospital at The Ohio State University, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard L","family":"Marini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Michigan Health System, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn","family":"Rudoni","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, University of Texas MD Anderson Cancer Center, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J","family":"Perissinotti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Michigan Health System, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"key":"bibr1-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29383"},{"key":"bibr2-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-015-0657-6"},{"key":"bibr3-1078155217713363","unstructured":"National Comprehensive Cancer Network. Acute lymphoblastic leukemia (Version 2), https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf (2016, accessed 22 April 2017)."},{"key":"bibr4-1078155217713363","unstructured":"National Cancer Institute. SEER cancer statistics factsheets: Acute lymphocytic leukemia (ALL), http:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html (2016, accessed 20 October 2016)."},{"key":"bibr5-1078155217713363","doi-asserted-by":"publisher","DOI":"10.5772\/26833"},{"key":"bibr6-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1517\/14728210903456026"},{"key":"bibr7-1078155217713363","doi-asserted-by":"crossref","unstructured":"Fullmer A, O\u2019Brien S, Kantarjian H, et al. Novel therapies for relapsed acute lymphoblastic leukemia.\n                      Curr Hematol Malig Rep\n                      2009; 4: 148\u2013156.","DOI":"10.1007\/s11899-009-0021-6"},{"key":"bibr8-1078155217713363","unstructured":"Cortes JE and Kantarjian HM. Acute lymphocytic leukemia.\n                      Leuk Lymphoma Oncol J\n                      , http:\/\/www.cancer.org\/acs\/groups\/cid\/documents\/webcontent\/003109-pdf.pdf (1995, accessed 23 May 2016)."},{"key":"bibr9-1078155217713363","unstructured":"National Cancer Institute. SEER cancer statistics review, 1975-2013. Bethesda, MD, http:\/\/seer.cancer.gov\/csr\/1975_2013\/ (2017, accessed 22 May 2017)."},{"key":"bibr10-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62187-4"},{"key":"bibr11-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.9023"},{"key":"bibr12-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-378943"},{"key":"bibr13-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8018"},{"key":"bibr14-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.251"},{"key":"bibr15-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900386"},{"key":"bibr16-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023001"},{"key":"bibr17-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232124"},{"key":"bibr18-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149286"},{"key":"bibr19-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1536"},{"key":"bibr20-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"bibr21-1078155217713363","first-page":"851","volume":"26","author":"Mathisen MS","year":"2012","journal-title":"Oncology"},{"key":"bibr22-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713"},{"key":"bibr23-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.7"},{"key":"bibr24-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.6065"},{"key":"bibr25-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837"},{"key":"bibr26-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.268"},{"key":"bibr27-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04058-6"},{"key":"bibr28-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390904"},{"key":"bibr29-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-580027"},{"key":"bibr30-1078155217713363","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S2941"},{"key":"bibr31-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072739"},{"key":"bibr32-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2146"},{"key":"bibr33-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"bibr34-1078155217713363","doi-asserted-by":"crossref","unstructured":"Kreike B, Hart G, Bartelink H, et al. Analysis of breast cancer related gene expression using natural splines and the Cox proportional model to identify prognostic associations.\n                      Breast Cancer Res Treat\n                      2010; 122: 711\u2013720.","DOI":"10.1007\/s10549-009-0588-6"},{"key":"bibr35-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1258"},{"key":"bibr36-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5"},{"key":"bibr37-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"bibr38-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051424"},{"key":"bibr39-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0284"},{"key":"bibr40-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.4565"},{"key":"bibr41-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611618104"},{"key":"bibr42-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052638"},{"key":"bibr43-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540"},{"key":"bibr44-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"bibr45-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"bibr46-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"bibr47-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"bibr48-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"bibr49-1078155217713363","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668"},{"key":"bibr50-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.187"},{"key":"bibr51-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2007.088"},{"key":"bibr52-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318270dec7"},{"key":"bibr53-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"bibr54-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"bibr55-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"bibr56-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"bibr57-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7002"},{"key":"bibr58-1078155217713363","unstructured":"Amgen Inc. Blincyto (package insert). Thousand Oaks, CA: Amgen Inc, 2014."},{"key":"bibr59-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93"},{"key":"bibr60-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10557"},{"key":"bibr61-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"bibr62-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4"},{"key":"bibr63-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12393"},{"key":"bibr64-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3703.3703"},{"key":"bibr65-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"bibr66-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1866"},{"key":"bibr67-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"bibr68-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"bibr69-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"bibr70-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23919"},{"key":"bibr71-1078155217713363","doi-asserted-by":"crossref","unstructured":"Martinelli G, Dombret H, Chevalier P, et\u00a0al. Complete molecular and hematologic response in adult patients with relapsed\/refractory (R\/R) Philadephia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA). In:\n                      American Society of Hematology (ASH) 57th annual meeting & exposition\n                      , Orlando, FL, 5\u20138 December 2015.","DOI":"10.1182\/blood.V126.23.679.679"},{"key":"bibr72-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.379.379"},{"key":"bibr73-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"bibr74-1078155217713363","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100073"},{"key":"bibr75-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25953"},{"key":"bibr76-1078155217713363","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"bibr77-1078155217713363","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp151052"},{"key":"bibr78-1078155217713363","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp151031"},{"key":"bibr79-1078155217713363","unstructured":"National Institutes of Health. Map of United States illustrating number of trials by state with clinical trials involving \u201cchimeric antigen receptor,\u201d https:\/\/clinicaltrials.gov\/ct2\/results\/map\/click?map.x=161&map.y=158&term=chimeric+antigen+receptor (2017, accessed 4 May 2017)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217713363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217713363","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217713363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:25Z","timestamp":1777688245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217713363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1177\/1078155217713363"],"URL":"https:\/\/doi.org\/10.1177\/1078155217713363","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,5]]}}}